News & Updates

Patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) who achieved an initial complete response (CR) to UGN-102 treatment tend to remain event-free 24 months later, according to phase III ENVISION trial.

Atherosclerotic cardiovascular disease (ASCVD) affects a substantial proportion of adults with β-thalassaemia. It appears to be driven by conventional CV risk factors rather than disease-specific features, according to research presented at EHA2026.

The novel small-protein IL-17 inhibitor izokibep demonstrates durable efficacy and a favourable safety profile over 52 weeks in patients with active psoriatic arthritis (PsA), with sustained improvements in joint, skin, and quality-of-life outcomes in a phase IIB/III study.